Ironwood Pharma (NASDAQ: IRWD) reported Q2 EPS of $0.21, $0.12 worse than the analyst estimate of $0.33. Revenue for the quarter came in at $97.23 million versus the consensus estimate of $103.55 million.

GUIDANCE:

Ironwood Pharma reiterates FY2022 revenue of $420-$430 million, versus the consensus of $428.80 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.